Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Immune dysregulation in myeloma and impact on disease progression

David Avigan • 26 Aug 2022
IMS 2022
Multiple Myeloma

David Avigan, MD, Harvard Medical School, Boston, MA, briefly discusses the importance of investigating immune dysregulation in patients with multiple myeloma, highlighting the role of T-cell exhaustion and how this may impact disease progression. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from David Avigan

2:26
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan • 26 Aug 2022
1:26
The role of vaccines in AML
David Avigan • 26 Aug 2022
3:31
Vaccines and immunotherapy in hematological malignancies
David Avigan • 8 Sep 2020
16:02
CAR-T: hurdles and ladders
Adam Cohen et al. • 13 Sep 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals